Global Antiviral Drugs Market, By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, m-RNA Synthesis Inhibitors, Integrase Inhibitors, Others), Indication (HIV, Hepatitis, Herpes Simplex Virus, Influenza, Others), Route of Administration (Oral, Topical, Parenteral Others), Type (Branded, Generics), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Antiviral Drugs Market Analysis and Size
In 2019, it has been witnessed that there were almost 37.9 million persons suffering form HIV/AIDS globally, according to a UNAIDS report. Within this, there are around 36.2 million adults, 1.7 million children, and 770,000 persons who died from this illness. Growing approval and estimated commercialization of novel medicines for different viral infections are projected to push the market growth. In this regard, broad-spectrum antiviral drugs can be used to treat a wide range of viruses.
Data Bridge Market Research analyses a growth rate in the antiviral drugs market in the forecast period 2023-2030. The expected CAGR of antiviral drugs market is around 4.7% in the mentioned forecast period. The market was valued at USD 59,135.29 million in 2022, and it would grow upto USD 85,392.59 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Antiviral Drugs Market Scope and Segmentation
2023 to 2030
2021 (Customizable to 2015 - 2020)
Revenue in USD Million, Volumes in Units, Pricing in USD
Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, m-RNA Synthesis Inhibitors, Integrase Inhibitors, Others), Indication (HIV, Hepatitis, Herpes Simplex Virus, Influenza, Others), Route of Administration (Oral, Topical, Parenteral Others), Type (Branded, Generics), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
AstraZeneca (U.K.), Lilly (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), GSK plc (U.K.), Hikma Pharmaceuticals PLC (U.K.), Cipla Inc. (India), Lupin (India), Laurus Labs (India), Micro Labs Ltd (India), Gilead Sciences, Inc, (U.S.) Amneal Pharmaceuticals LLC. (U.S.), Alembic Pharmaceuticals Limited (India), Zydus Group (India), and Bausch Health Companies Inc. (Canada)
Antiviral drugs are the class of antimicrobials therapeutics used extensively in treating several viral infections. The antiviral agents have distinct mechanism of action that includes the inhibition of viral DNA synthesis and thus prevent it from replication. Some of the antiviral drugs acts on protease enzymes and prevent it from further cell division.
Antiviral Drugs Market Dynamics
- Rising Demand of Antiviral Drugs
There are numerous infections that spreads through fluid that are present in the air droplets after individual coughs or sneezes. These fluids enter into the body via mouth or nose. Several treatment options such as acyclovir and oseltamivir are used to treat the antiviral infection. Similarly, these drugs help decrease the severity of flu virus by spreading into the body, further improving the market progression. Therefore, more and more consumption of antiviral drugs acts as a major driver of growth in the market.
- Growing Prevalence of Hepatitis
According to WHO records, an estimated 325 million people are suffering with hepatitis infection and out of these, about 71 million have chronic hepatitis C virus infection. Furthermore, the U.S. Department of Health and Human Services has estimated that 2.4 million people are living with hepatitis C in the U.S. and about 850,000 individuals in the country have hepatitis B infection. A growing base of patients is expected to increase the demand for antiviral drugs worldwide.
- Growing Approvals From Several Organizations
Growing approval and expected commercialization of several novel medicines for viral infections are estimated to drive the market growth. For instance, in November 2020, the U.S. FDA has approved a supplemental New Drug Application for Roche’s Xofluza for treating influenza patients in patients 12 years of age and older. Furthermore, the major players in the market have launched many novel medicines in the last 2 to 3 years for the treatment of several viral infections. For instance, Gilead Sciences, Inc. has launched Biktarvy, Symtuza, and Veklury for the treatment of viral infections. Thus, this factor increases the market growth.
- Increasing Strategic Collaborations with Different Organizations
Increasing collaborations for developing and manufacturing different antiviral drugs are anticipated to result in the development of a huge number of novel drugs in the upcoming years. The major market players are collaborating for the R&D of new therapies to decrease the burden of viral infection treatment. For instance, in 2020, Gilead Sciences, Inc. has signed licensing agreement with top pharmaceutical manufacturers such as Hetero Labs Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Mylan, and others to expand the supply of remdesivir.
- Lack Of Skilled Professionals
The lack of skilled healthcare professionals who cannot treat the patients appropriately with particular treatments could limit the growth of the global antiviral drugs market during the forecast period.
- Demand for alternative medicines
The huge demand for alternative medicines such as naturopathy and homeopathy are restricting the market growth. These medicines blend traditional medicine along with conventional healthcare to work with the body naturally. Thus, patient choose these medications instead of drugs and are thus restricting the market growth.
This antiviral drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the antiviral drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Antiviral Drugs Market
The COVID-19 pandemic has increased antiviral medicine sales. Numerous pharmaceutical companies are focusing on new drug development to provide effective treatment and better patient outcomes. Governments are taking numerous initiatives to fight COVID-19. For instance, in May 2020, the Centers for Disease Control and Prevention started working with the All-of-Government and All-of-America Approach to surge testing capacity, improve case detection, and contact tracing across all regions in the U.S. and to re-open the country. Governments are giving quick approval for fast scale-up, which can help them reopen economics. To date, there is no available treatment for Covid-19 and most companies are trying to use existing drugs for novel corona virus.
- In 2021, the U.S. government announced an investment of more than USD 3 billion to increase the discovery, development, and manufacturing of several antiviral medicines for COVID-19 treatment. The increasing disease prevalence and R&D will surge the demand for antiviral drugs in the next 2 to 3 years.
Global Antiviral Drugs Market Scope
The antiviral drugs market is segmented on the basis of drug class, infection, type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- DNA Polymerase Inhibitors
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- m-RNA Synthesis Inhibitors
- Integrase Inhibitors
- Herpes Simplex Virus
Route of Administration
- Specialty Clinics
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Antiviral Drugs Market Regional Analysis/Insights
The antiviral drugs market is analyzed and market size insights and trends are provided by drug class, infection, type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the antiviral drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for antiviral drugs market throughout the forecasted period due to the high commonness of viral diseases, presence of global key market players and wide availability of advanced treatment.
Asia-Pacific dominates the market because of the developing healthcare facilities and increase in government initiatives.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Antiviral Drugs Market Share Analysis
The antiviral drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to antiviral drugs market.
Key players operating in the antiviral drugs market include:
- AstraZeneca (U.K.)
- Lilly (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Novartis AG (Switzerland)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Merck & Co., Inc. (U.S.)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Hikma Pharmaceuticals PLC (U.K.)
- Cipla Inc. (India)
- Lupin (India)
- Laurus Labs (India)
- Micro Labs Ltd (India)
- Gilead Sciences, Inc, (U.S.)
- Amneal Pharmaceuticals LLC. (U.S.)
- Alembic Pharmaceuticals Limited (India)
- Zydus Group (India)
- Bausch Health Companies Inc. (Canada)